Several epidemiologic studies have indicated reduced risk of dementia among users of statins. We assessed the risk of hospitalization with dementia associated with use of statins in a population-based case-control study in 4 Northern Danish counties in the period 1991 to 2005. We identified 11,039 cases with dementia and 110,340 age-matched and sex-matched population controls using data from the National Patient Registry, the Danish Psychiatric Central Register, and the Civil Registration System. Prescriptions for statins filled before the admission for dementia were identified using population-based prescription databases. We used conditional logistic regression analysis to compute relative risk of hospitalization with dementia associated with use of statins using nonusers as reference group. We found an overall reduced risk of hospitalization with dementia among statin users (adjusted odds ratio: 0.67, 95% confidence intervals: 0.60-0.75). The reduced risk associated with statin use remained robust in various subanalyses, however, we found no clear dose-response pattern between the number of filled prescriptions for statin and the risk of hospitalization with dementia. In conclusion, we found a reduced risk of hospitalization with dementia among users of statins, however, whether this association is causal remains to be clarified.
V ascular and lipid-related mechanisms are thought to have a role in the pathogenesis of both Alzheimer disease and vascular dementia. 1, 2 It is, therefore, possible that treatment with lipid-lowering drugs, including statins, could lessen the risk of dementia and slow the progression of the disease. In addition to their beneficial effects on cholesterol levels, statins have other pharmacologic effects that may influence the pathogenesis of Alzheimer disease and dementia, including anti-inflammatory, antioxidant, and neuroprotective effects. 3 However, the epidemiologic evidence is contradictory. Several observational studies, primarily case-control and cross-sectional studies, have shown a protective role of statins, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] but a number of cohort studies have not found a clear association between statins and reduced risk of dementia. 6, 10, 14 Most randomized controlled trials have not demonstrated any protective effect of statins, but it should be noted that many of those published so far were primarily designed to evaluate the vascular effects, using cognitive function as a surrogate measure for dementia only as a secondary end point. 17, 18 Results from a recent randomized controlled trial with a 1year exposure to either atorvastatin or placebo found that statins may have a positive effect on the progressive deterioration of cognitive function and behaviors anticipated in mild to moderate Alzheimer disease. 19 The lack of consistency in the existing observational studies may reflect differences in the study design and analytic methods. Also, the potential effects of indication bias may influence the results as patients prescribed statins may have a lower baseline risk of dementia compared with other patients. This hypothesis is supported by the fact that some physicians might be less motivated to prescribe longterm preventive agents to patients who shows signs of cognitively impairment. 20, 21 Further, unaccounted confounding, such as socioeconomic factors, could also affect the results of the observational studies. Physicians may be more likely to prescribe statins to patients who are highly educated, who have knowledge about the drugs, who are concerned about their future health, and who actually ask for the prescriptions/treatment. 22 Here we conducted a large population-based casecontrol study based on prospectively collected data to further explore the association between use of statins and the risk of hospitalization with dementia.
METHODS

Study Population
We conducted the study within the population of North Jutland, Aarhus, Viborg, and Ringkøbing Counties, Denmark from January 1, 1991 to December 31, 2005. The National Health Service provides tax-supported healthcare for all inhabitants in Denmark, that is, guaranteeing free access to general practitioners and hospitals, and refunds a variable proportion of costs of medication prescribed by physicians. Since 1968, the Danish Civil Registration System has maintained electronic records of the entire Danish population and assigned a unique identification number (ie, the civil registry number) to all Danish residents at birth. All services are registered by use of the civil registry number, and it is used in all public Danish registers. Use of the civil registry number secures valid linkage between various population-based registers.
Cases of Dementia
We used computerized data from the National Patient Registry 23 and the Danish Psychiatric Central Register 24 to identify cases hospitalized with dementia in North Jutland (January 1992 to December 2005), Aarhus (January 1997 to December 2005), and Viborg and Ringkøbing (January 1999 to December 2005) corresponding to the availability of computerized prescription data with a minimum length of prescription history for all cases and controls of 1 year.
The National Patient Registry, established in the year 1977, store data on all discharges from nonpsychiatric hospitals in the county, including the civil registry number, dates of admission and discharge, surgical procedure(s) performed, and up to 20 discharge diagnoses assigned by the treating physician, whereas the Danish Psychiatric Central Register, established in the year 1969, store data on all discharges from all psychiatric hospitals and psychiatric departments in general hospitals, including the civil registry number, dates of admission and discharge, and all diagnoses assigned by the treating physician.
The diagnoses were classified according to the Danish version of the International Classification of Diseases (ICD), 8th until the end of 1993 and the 10th revision thereafter. On the basis of the data going back to 1977 or 1969, we constructed the hospital history for all persons, who were residents in the counties, and hereafter identified all patients, who were registered with a diagnosis of dementia (ICD-8: 29009, 29010, 29018, 29019, 29309, 29319; ICD-10: F00, F01, F03, G30) during the study period. Among these cases, we further identified patients with Alzheimer disease (ICD-8: 29010; ICD-10: F00, G30). After excluding cases that were not residents in the counties at study start and cases with unconfirmed diagnoses of dementia during the hospital stay (modification code 1 or 2 in the ICD-8 period), a total of 11,039 cases were available for analysis.
Population Controls
For each dementia case, we aimed to identify 10 agematched and sex-matched controls from the general population of the county through the Civil Registration System using risk set sampling, 25 that is, the controls had to be alive and at risk of hospitalization with dementia at the time the corresponding case was diagnosed (index date). The Civil Registration System is updated daily, keeps electronic records on vital status (dead or alive), date of death, and residence of all Danish inhabitants. We identified a total of 110,340 population controls.
Data on Statin Use
We used the population-based prescription databases 26 of North Jutland, Aarhus, Viborg, and Ringkøbing to obtain data on prescriptions for statins, as statins are only available by prescription in Denmark. The databases were initiated on January 1, 1991 in North Jutland, 1996 in Aarhus, and 1998 in Viborg and Ringkøbing.
The counties are served by pharmacies equipped with electronic accounting systems that are primarily used to secure reimbursement from the Danish National Health Service. The registered data include type of drug and the date the prescription is filled.
We identified all prescriptions for statins [fluvastatin, simvastatin, atorvastatin, pravastatin, lovastatin, cerivastatin, and rosuvastatin (ATC codes: C10AA01-07, B04AB01-04)] filled by cases and controls before the index date. The cases and controls were then classified according to their use of statins: either having filled no prescriptions of statins in the last 5 years or having filled 1 or more prescriptions of statins within the last 5 years. Users of statins within the last 5 years were further classified according to their total number of filled prescriptions within the 5 years, that is, 1 to 4 prescriptions, 5 to 10 prescriptions, 11 to 19 prescriptions, and >19 prescriptions.
Data on Possible Confounding Factors
Data on possible confounding factors were obtained from the National Patient Registry, the prescription databases, and the Prevention Registry at Statistics Denmark. We obtained information on prior discharge diagnoses of hypertension, stroke, ischemic heart disease, invasive coronary revascularizations, alcohol-related diseases, diabetes mellitus, and chronic bronchitis and emphysema (as a proxy for severe smoking) from the National Patient Registry. Data from the prescription databases included all prescriptions for other lipid-lowering drugs than statins, antiplatelets, antihypertensives, highdose aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, peroral anticoagulants, hormone replacement therapy, and insulin and other antidiabetic drugs filled within 5 years before hospitalization with dementia or the corresponding date for controls.
Data on socioeconomic status of both cases and controls were obtained from the Prevention Registry at Statistics Denmark. 27 This registry collects data from several other registers, that is, health-related registers, registers on living conditions, and registers of population statistics. The cases and controls were classified according to marital status (single, married, or cohabiting), employment status (old-age pensioner, self-employed, or salaried employed), gross income (below 20th percentile, 20th to 40th, 40th to 60th, 60th to 80th, or above 80th percentile), and educational level (university degree, short/mediumterm formal education, basic vocational education, or unspecified).
Statistical Analysis
We formed contingency tables and used conditional logistic regression analysis to compute crude and adjusted odds ratios (ORs) of hospitalization with dementia according to use of statins. As we used risk set sampling of controls, these ORs are unbiased estimates of the corresponding incidence rate ratio. 25 Nonusers were used as the reference group in all analyses. We adjusted for a previous history of hypertension, stroke, ischemic heart disease, invasive coronary revascularizations, alcohol-related diseases, diabetes mellitus, chronic bronchitis, and emphysema, and for current use of other lipid-lowering drugs than statins, antiplatelets, antihypertensives, high-dose aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, peroral anticoagulants, hormone replacement therapy, and socioeconomic status in the logistic regression analyses. Information on socioeconomic status was missing for a part of the study population, and these subjects were given a separate ''missing'' classification for those variables for inclusion in the adjusted models. We also did the analyses excluding these subjects. We further restricted the analyses to cases with Alzheimer disease and their controls. Stratified analyses were performed by age, sex, calendar time period (1992 to 2000 and 2001 to 2005), and prior cardiovascular disease (stroke, ischemic heart disease, and invasive coronary revascularizations). All analyses were performed using SAS version 8.02 (SAS Institute Inc, Cary, NC). Table 1 shows the descriptive data for the 11,039 dementia cases and 110,340 controls.
RESULTS
Among cases and controls, 389 (3.5%) and 4855 (4.4%), respectively, filled at least 1 prescription for statins in the last 5 years before a hospital diagnosis of dementia or index date among controls. Hypertension, stroke, ischemic heart disease, alcohol-related disease, diabetes mellitus, chronic bronchitis, and emphysema were more prevalent among cases than controls, and more cases than controls had filled prescriptions for antiplatelets, antihypertensives, high-dose aspirin, insulin, and oral antidiabetic drugs. Cases were also more likely to be single and old-age pensioner.
After adjusting for possible confounding factors and further adjustment for socioeconomic status, use of statins was associated with a reduced risk of hospitalization with dementia [adjusted OR: 0.63 and 0.67, 95% confidence interval (CI): 0.56-0.70 and 0.60-0.75, respectively] ( Table 2) . The result was similar when excluding cases and controls with missing information on socioeconomic status (adjusted OR: 0.68, 95% CI: 0.60-0.78).
We found no clear association between the number of filled prescriptions for statins and risk of hospitalization with dementia; the adjusted ORs were 0.53 (95% CI: 0.43-0.67), 0.78 (95% CI: 0.63-0.96), 0.57 (95% CI: 0.45-0.71), and 0.86 (95% CI: 0.69-1.06) for 1 to 4 prescriptions, 5 to 10 prescriptions, 11 to 19 prescriptions, and >19 prescriptions, respectively.
The association between statin use and risk of hospitalization with dementia remained robust in all subanalyses when stratifying by age, sex, calendar period, and prior cardiovascular disease. The lowest risk estimates associated with statin use were found among patients younger than 60 years (adjusted OR: 0.48, 95% CI: 0.19-1.21) or 80 years or older (adjusted OR: 0.55, 95% CI: 0.44-0.68) and among patients with prior cardiovascular disease (adjusted OR: 0.46, 95% CI: 0.38-0.56). Results were also similar when restricting the analyses to cases with Alzheimer disease (adjusted OR: 0.72, 95% CI: 0.57-0.91).
In contrast, use of hormone replacement therapy among women was not associated with risk of hospitalization with dementia (adjusted OR: 0.96, 95% CI: 0.89-1.02).
Finally, we also looked at the risk estimates obtained for some of the known risk factors for dementia in our analyses to qualify the validity of our dataset. The adjusted ORs for a history of hypertension, stroke, or diabetes mellitus were 1.22 (95% CI: 1.15-1.30), 1.84 (95% CI: 1.72-1.96), and 1.58 (95% CI: 1.46-1.71), respectively.
DISCUSSION
In this population-based case-control study, users of statins had a clearly decreased risk of hospitalization with dementia. The association seemed not to be explained by a wide range of possible confounding factors, including socioeconomic factors, and the association remained robust in subanalyses stratified by age, sex, calendar time period, and prior cardiovascular disease, and when restricting the analyses to cases with Alzheimer disease. However, we found no clear association between numbers of filled prescriptions for statin and the risk of hospitalization with dementia. The main strengths of our study included the population-based design, and the ability to link different data sources with prospectively collected data. By use of these databases, the potential difficulties with recall bias are avoided.
Although the overall positive predictive value of a dementia diagnosis recorded in the National Patient Registry and the Danish Psychiatric Central Register is high (ie, approximately 85%), 28 an important limitation was the lack of details about the dementia diagnosis among the cases, including type of dementia and onset of symptoms. This information is relevant as the effects of statins on vascular dementia and Alzheimer disease may differ and as dementia is commonly first recognized or diagnosed several years after symptom onset. If an individual has early signs or symptoms of dementia, physicians might be less inclined to maintain preventive treatment, when the overall health deteriorates, 29 introducing indication bias in which an individual with prevalent or early dementia has less chance of receiving treatment than the control. The latter seemed not to be a major problem in our study as more cases than controls filled prescriptions for other drugs used for long-term primary and secondary prevention of cardiovascular disease, for example, antihypertensives and antiplatelets. Another limitation of our study includes lack of information on nonhospitalized dementia cases. However, this most likely leads to nondifferential misclassification and will thus bias the estimates toward unity. Similarly, any Berksons bias or surveillance bias arising owing to a potential increased probability of users of statins to be registered with a dementia diagnosis would also result in conservative risk estimates.
It has previously been discussed that statin users may be ''healthy users''-younger, healthier, better educated, and socioeconomically privileged persons-who may be more likely to receive preventive treatments than the less privileged and frail. 30 In general, severe confounding by socioeconomic differences is unlikely given Denmark's universal healthcare. However, we have recently reported a weak socioeconomic gradient in statin use among Danish men in the mid 90s, 31 indicating that socioeconomic factors could also be a confounding factor in the association between use of statins and risk of dementia. However, such an explanation in unlikely as the gradient was not found among women and that it decreased in magnitude over time among men. Some of the existing observational studies that found a reduced risk of dementia did adjust for educational level as a crude measure of socioeconomic status. [5] [6] [7] [8] [9] 15 We added marital status, employment status, and gross income to get a better measure of socioeconomic status. 32, 33 After adjustment for these factors, we still found a decreased risk of dementia among statin users. Notably, use of hormone replacement therapy in women, which may also be subject to the ''healthy user effect,'' had no effect on the risk of hospitalization with dementia in our study.
Although we adjusted for a number of confounding factors, we can, however, still not entirely exclude the possibility that our results remain influenced by residual, unmeasured, or unknown confounding.
Finally, it should be noted that despite the relatively large sample size, the low frequency of statin use among cases and controls in our study resulted in limited statistical precision for several of the presented risk estimates as indicated by the relatively wide confidence intervals. This low use of statins reflects a general low use of statins in Denmark. 34, 35 Our finding that users of statins have an overall reduced risk of dementia is in agreement with other observational studies. 4, 5, [7] [8] [9] [11] [12] [13] 19 We found no association between the number of filled prescriptions for statins and the risk of hospitalization with dementia, which is consistent with the lack of a doseresponse relationship between use of statins and dementia in other observational studies, 10, [12] [13] [14] and suggests that statins may not directly cause the reduced risk of dementia. However, an increased number of statin prescriptions could possibly also reflect more severe cardiovascular disease, which overwhelms the potential beneficial effects of the increased statin dosage.
Besides the beneficial effect on cholesterol levels, statins have other pharmacologic effects that may influence the pathogenesis of Alzheimer disease and dementia. The possible biologic mechanisms include (1) stimulation of asecretase activity, 36 (2) modulation of amyloid precursor protein metabolism and Ab production, 37 (3) immunomodulation leading to attenuation of inflammatory markers (eg, C-reactive protein and cytokines), 38, 39 (4) reduction of lipoprotein oxidation and free radical injury, 40 (5) increase in cerebral endothelial nitric oxide synthase and *Adjusted for use of antiplatelets, antihypertensives, high-dose aspirin, nonaspirin NSAIDs, peroral anticoagulants, lipid-lowering drugs, and hormone replacement therapy, and previous diagnoses of hypertension, stroke, ischemic heart disease, invasive coronary revascularization, alcohol-related diseases, diabetes mellitus, and chronic bronchitis or emphysema (as a proxy for smoking).
wAdjusted for marital status, employment stratus, gross income, educational level, use of antiplatelets, antihypertensives, high-dose aspirin, nonaspirin NSAIDs, peroral anticoagulants, lipid-lowering drugs, and hormone replacement therapy, and previous diagnoses of hypertension, stroke, ischemic heart disease, invasive coronary revascularization, alcohol-related diseases, diabetes mellitus, and chronic bronchitis or emphysema (as a proxy for smoking). CI indicates confidence interval; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio. cerebral circulation, 41 and (6) activation of signal transcription (Rho-GTPases) through depletion of downstream isopreniods. 42 In conclusion, we found a reduced risk of hospitalization with dementia among users of statins, and our findings, therefore, provide some support to the hypothesis that statins may protect against the development of dementia.
